Supernus Announces Issuance of Eighth U.S. Patent Protecting Trokendi XR

Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on January 31, 2017 of an eighth patent by the United States Patent and Trademark Office covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.

Tyme Announces Issuance of Second Core Platform Patent

Tyme Technologies, Inc. , a clinical stage biotechnology company developing cancer therapeutics that are designed to be effective across multiple tumor types, announced that the USPTO has issued patent number 9,549,969 . This substantially expands on issued patent number 8,481,498 in respect to using tyrosine derivatives in combination with agents that may increase oxidative stress to cause tumor cell death.

Cellect Receives Patent Notice of Allowance from US Patent &…

Cellect Biotechnology Ltd. , a developer of stem cells isolation technology, announces today that it has received a formal notice of allowance around a key method of treatment patent from the United States Patent & Trademark Office. The allowed claims relate to the engineering of regulatory immune cells with enhanced apoptotic activity to be used for immunomodulation for treating or preventing immune related disorders.